Sagimet Biosciences (SGMT) 8th Annual MASH Investor Conference summary

Company overview and therapeutic focus

• Clinical-stage biopharma focused on fatty acid synthase (FASN) inhibition for conditions like MASH, acne, and solid tumors.

• Lead molecule uniquely targets fat, inflammation, and fibrosis in MASH, with FDA breakthrough designation.

Clinical trial results and differentiation

• Phase II-B FASCINATE-2 trial met both primary endpoints, showing significant fibrosis improvement without worsening MASH.

• In F3 fibrosis patients, 49% showed ≥1 stage improvement vs. 13% for placebo; 34% showed ≥2 stage improvement vs. 4% for placebo.

• Drug outperformed all competitors with one-year data and is expected to surpass two-year results of others.

• Twice as many placebo patients progressed to cirrhosis compared to those on denifanstat.

Biomarker and precision medicine insights

• Tripalmitin decline correlates with FASN inhibition and early treatment response, detectable as early as four weeks.

• Ongoing analysis of tripalmitin's correlation with biopsy and other metabolic markers; data to be presented at EASL next year.